CN101953819A - 施用罗替戈汀的改良透皮递药系统 - Google Patents
施用罗替戈汀的改良透皮递药系统 Download PDFInfo
- Publication number
- CN101953819A CN101953819A CN2010102984651A CN201010298465A CN101953819A CN 101953819 A CN101953819 A CN 101953819A CN 2010102984651 A CN2010102984651 A CN 2010102984651A CN 201010298465 A CN201010298465 A CN 201010298465A CN 101953819 A CN101953819 A CN 101953819A
- Authority
- CN
- China
- Prior art keywords
- rotigotine
- tds
- matrix
- adhesive
- self
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 title claims abstract description 92
- 229960003179 rotigotine Drugs 0.000 title claims abstract description 89
- 230000037317 transdermal delivery Effects 0.000 title description 4
- 239000011159 matrix material Substances 0.000 claims abstract description 76
- 239000000853 adhesive Substances 0.000 claims abstract description 48
- 229920000642 polymer Polymers 0.000 claims abstract description 18
- 239000012458 free base Substances 0.000 claims abstract description 16
- 239000011888 foil Substances 0.000 claims abstract description 11
- 230000001681 protective effect Effects 0.000 claims abstract description 11
- 239000007787 solid Substances 0.000 claims abstract description 11
- 238000013271 transdermal drug delivery Methods 0.000 claims abstract description 6
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 3
- 230000001070 adhesive effect Effects 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 20
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 18
- 229920001296 polysiloxane Polymers 0.000 claims description 16
- -1 polysiloxane Polymers 0.000 claims description 12
- 229920005989 resin Polymers 0.000 claims description 9
- 239000011347 resin Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 6
- 238000003860 storage Methods 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 230000004907 flux Effects 0.000 abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 42
- 239000003814 drug Substances 0.000 description 42
- 229940079593 drug Drugs 0.000 description 41
- 210000003491 skin Anatomy 0.000 description 32
- 239000000243 solution Substances 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 14
- 238000010521 absorption reaction Methods 0.000 description 13
- 239000010408 film Substances 0.000 description 13
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
- CEXBONHIOKGWNU-NTISSMGPSA-N hydron;(6s)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol;chloride Chemical compound [Cl-].CCC[NH+]([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 CEXBONHIOKGWNU-NTISSMGPSA-N 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 229920000728 polyester Polymers 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000013464 silicone adhesive Substances 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 238000009792 diffusion process Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000003475 lamination Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 3
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 3
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 3
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 3
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007970 homogeneous dispersion Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 230000005588 protonation Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- KFQYTPMOWPVWEJ-UHFFFAOYSA-N 6-{propyl[2-(thiophen-2-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-1-ol Chemical compound C1CC2=C(O)C=CC=C2CC1N(CCC)CCC1=CC=CS1 KFQYTPMOWPVWEJ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 229940123603 Dopamine D2 receptor antagonist Drugs 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 235000010044 Hernandia moerenhoutiana Nutrition 0.000 description 1
- 244000084296 Hernandia moerenhoutiana Species 0.000 description 1
- 101000807540 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 25 Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102100037179 Ubiquitin carboxyl-terminal hydrolase 25 Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229920001688 coating polymer Polymers 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- LRCFXGAMWKDGLA-UHFFFAOYSA-N dioxosilane;hydrate Chemical compound O.O=[Si]=O LRCFXGAMWKDGLA-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- ZJQPLBFKBQYYIO-UHFFFAOYSA-N dodecasodium;trisilicate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] ZJQPLBFKBQYYIO-UHFFFAOYSA-N 0.000 description 1
- 239000000442 dopamine 2 receptor blocking agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 229910052909 inorganic silicate Inorganic materials 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02016860A EP1386605A1 (en) | 2002-07-30 | 2002-07-30 | Improved transdermal delivery system for the administration of rotigotine |
| EP02016860.5 | 2002-07-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA038184257A Division CN1671375A (zh) | 2002-07-30 | 2003-07-28 | 施用罗替戈汀的改良透皮递药系统 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101953819A true CN101953819A (zh) | 2011-01-26 |
Family
ID=30011090
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102984651A Pending CN101953819A (zh) | 2002-07-30 | 2003-07-28 | 施用罗替戈汀的改良透皮递药系统 |
| CNA038184257A Pending CN1671375A (zh) | 2002-07-30 | 2003-07-28 | 施用罗替戈汀的改良透皮递药系统 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA038184257A Pending CN1671375A (zh) | 2002-07-30 | 2003-07-28 | 施用罗替戈汀的改良透皮递药系统 |
Country Status (19)
| Country | Link |
|---|---|
| EP (2) | EP1386605A1 (https=) |
| JP (2) | JP4837916B2 (https=) |
| KR (1) | KR101016838B1 (https=) |
| CN (2) | CN101953819A (https=) |
| AT (1) | ATE322263T1 (https=) |
| AU (1) | AU2003258539B2 (https=) |
| BR (1) | BR0313091A (https=) |
| CA (1) | CA2491366A1 (https=) |
| DE (1) | DE60304477T2 (https=) |
| DK (1) | DK1524975T3 (https=) |
| ES (1) | ES2256780T3 (https=) |
| IL (1) | IL165918A0 (https=) |
| MX (1) | MXPA05000350A (https=) |
| NO (1) | NO333297B1 (https=) |
| PL (1) | PL217079B1 (https=) |
| PT (1) | PT1524975E (https=) |
| SI (1) | SI1524975T1 (https=) |
| WO (1) | WO2004012730A1 (https=) |
| ZA (1) | ZA200500252B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106604748A (zh) * | 2014-05-21 | 2017-04-26 | Sk化学株式会社 | 具有改进的稳定性的含有罗替戈汀的经皮吸收制剂 |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10041478A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| EP1386605A1 (en) * | 2002-07-30 | 2004-02-04 | Schwarz Pharma Ag | Improved transdermal delivery system for the administration of rotigotine |
| EP1386604A1 (en) * | 2002-07-30 | 2004-02-04 | Schwarz Pharma Ag | Improved transdermal delivery system |
| DE10361259A1 (de) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes |
| DE10361258A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
| DE102004014841B4 (de) | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
| WO2006039532A2 (en) * | 2004-09-29 | 2006-04-13 | Schwarz Pharma, Inc. | Transdermal therapeutic system for parkinson’s disease |
| US7353034B2 (en) | 2005-04-04 | 2008-04-01 | X One, Inc. | Location sharing and tracking using mobile phones or other wireless devices |
| EP2349230A2 (en) * | 2008-10-06 | 2011-08-03 | Mylan Technologies, Inc. | Amorphous rotigotine transdermal system |
| DE102008060203A1 (de) | 2008-12-07 | 2010-06-10 | Dietrich Wilhelm Schacht | Wirkstoffstabilisierende flächenförmige Vorrichtung |
| EP2201941A1 (de) | 2008-12-29 | 2010-06-30 | UCB Pharma GmbH | Pflaster-Herstellungstechnologie |
| US9925150B2 (en) * | 2009-12-22 | 2018-03-27 | Lts Lohmann Therapie-Systeme Ag | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
| MX2012012069A (es) | 2010-04-30 | 2012-11-22 | Teikoku Pharma Usa Inc | Composiciones transdermicas de propinilaminoindan. |
| KR101853082B1 (ko) | 2011-03-24 | 2018-04-27 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 활성제층 및 활성제 변환층을 포함하는 경피 조성물 |
| EP2559435A1 (en) | 2011-08-19 | 2013-02-20 | UCB Pharma GmbH | Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke |
| JP5913614B2 (ja) | 2011-11-09 | 2016-04-27 | テイコク ファーマ ユーエスエー インコーポレーテッド | 皮膚新生物の処置方法 |
| DE102011119043A1 (de) | 2011-11-22 | 2013-05-23 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System (TDS) mit Rotigotin |
| DE102011090178A1 (de) | 2011-12-30 | 2013-07-04 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation |
| KR101558042B1 (ko) * | 2012-07-05 | 2015-10-07 | 에스케이케미칼주식회사 | 로티고틴을 함유한 경피흡수제제 |
| JP6050896B2 (ja) | 2012-11-02 | 2016-12-21 | テイコク ファーマ ユーエスエー インコーポレーテッド | プロピニルアミノインダン経皮組成物 |
| TW201431570A (zh) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片 |
| JP2016135744A (ja) * | 2013-05-08 | 2016-07-28 | 株式会社 ケイ・エム トランスダーム | 貼付剤 |
| US20160199316A1 (en) | 2013-06-14 | 2016-07-14 | Tesa Labtec Gmbh | Three-layer transdermal therapy system (tts) |
| WO2014198422A1 (de) | 2013-06-14 | 2014-12-18 | Tesa Labtec Gmbh | Transdermales therapiesystem (tts) mit rotigotin |
| EP3016641B1 (de) | 2013-07-03 | 2018-09-05 | LTS Lohmann Therapie-Systeme AG | Transdermales therapeutisches system mit elektronischem bauteil |
| EP3145502B1 (en) | 2014-05-20 | 2022-07-06 | LTS Lohmann Therapie-Systeme AG | Transdermal delivery system containing rotigotine |
| US11752110B2 (en) | 2014-05-20 | 2023-09-12 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an interface mediator |
| WO2015177209A1 (en) * | 2014-05-20 | 2015-11-26 | Lts Lohmann Therapie-Systeme Ag | Method for adjusting the release of active agent in a transdermal delivery system |
| CN104382850B (zh) * | 2014-10-17 | 2017-12-22 | 烟台大学 | 一种罗替戈汀微乳及微乳凝胶 |
| WO2019234662A1 (en) * | 2018-06-07 | 2019-12-12 | Nal Pharmaceutical Group Limited | Transdermal drug delivery system containing rotigotine |
| DK3854388T3 (da) | 2020-01-24 | 2023-11-27 | Luye Pharma Switzerland Ag | Transdermalt terapeutisk system omfattende rotigotin og mindst et ikke-aminresistent silikoneklæbestof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5989586A (en) * | 1992-10-05 | 1999-11-23 | Cygnus, Inc. | Two-phase matrix for sustained release drug delivery device |
| AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
| DE19814083C2 (de) * | 1998-03-30 | 2002-02-07 | Lohmann Therapie Syst Lts | Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen |
| DE19814084B4 (de) * | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
| DE19940238A1 (de) * | 1999-08-25 | 2001-03-01 | Lohmann Therapie Syst Lts | Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten |
| EP1256340B1 (en) * | 2001-05-08 | 2003-08-13 | Schwarz Pharma Ag | Improved transdermal therapeutic system for the treatment of Parkinson's disease |
| EP1386604A1 (en) * | 2002-07-30 | 2004-02-04 | Schwarz Pharma Ag | Improved transdermal delivery system |
| EP1386605A1 (en) * | 2002-07-30 | 2004-02-04 | Schwarz Pharma Ag | Improved transdermal delivery system for the administration of rotigotine |
-
2002
- 2002-07-30 EP EP02016860A patent/EP1386605A1/en not_active Withdrawn
-
2003
- 2003-07-28 PL PL374814A patent/PL217079B1/pl unknown
- 2003-07-28 DK DK03766331T patent/DK1524975T3/da active
- 2003-07-28 MX MXPA05000350A patent/MXPA05000350A/es active IP Right Grant
- 2003-07-28 DE DE60304477T patent/DE60304477T2/de not_active Expired - Lifetime
- 2003-07-28 WO PCT/EP2003/008320 patent/WO2004012730A1/en not_active Ceased
- 2003-07-28 CA CA002491366A patent/CA2491366A1/en not_active Abandoned
- 2003-07-28 AU AU2003258539A patent/AU2003258539B2/en not_active Expired
- 2003-07-28 ES ES03766331T patent/ES2256780T3/es not_active Expired - Lifetime
- 2003-07-28 SI SI200330224T patent/SI1524975T1/sl unknown
- 2003-07-28 CN CN2010102984651A patent/CN101953819A/zh active Pending
- 2003-07-28 BR BR0313091-6A patent/BR0313091A/pt not_active Application Discontinuation
- 2003-07-28 CN CNA038184257A patent/CN1671375A/zh active Pending
- 2003-07-28 PT PT03766331T patent/PT1524975E/pt unknown
- 2003-07-28 JP JP2004525349A patent/JP4837916B2/ja not_active Expired - Lifetime
- 2003-07-28 KR KR1020057001233A patent/KR101016838B1/ko not_active Expired - Lifetime
- 2003-07-28 AT AT03766331T patent/ATE322263T1/de active
- 2003-07-28 EP EP03766331A patent/EP1524975B9/en not_active Expired - Lifetime
-
2004
- 2004-12-22 IL IL16591804A patent/IL165918A0/xx unknown
-
2005
- 2005-01-11 ZA ZA2005/00252A patent/ZA200500252B/en unknown
- 2005-01-27 NO NO20050472A patent/NO333297B1/no not_active IP Right Cessation
-
2011
- 2011-06-15 JP JP2011133638A patent/JP5564469B2/ja not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106604748A (zh) * | 2014-05-21 | 2017-04-26 | Sk化学株式会社 | 具有改进的稳定性的含有罗替戈汀的经皮吸收制剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2256780T3 (es) | 2006-07-16 |
| PL374814A1 (en) | 2005-10-31 |
| CN1671375A (zh) | 2005-09-21 |
| DE60304477D1 (de) | 2006-05-18 |
| JP2011219485A (ja) | 2011-11-04 |
| MXPA05000350A (es) | 2005-03-31 |
| EP1524975B9 (en) | 2012-02-22 |
| JP2005535687A (ja) | 2005-11-24 |
| AU2003258539A1 (en) | 2004-02-23 |
| PL217079B1 (pl) | 2014-06-30 |
| EP1524975A1 (en) | 2005-04-27 |
| WO2004012730A1 (en) | 2004-02-12 |
| KR20050056942A (ko) | 2005-06-16 |
| KR101016838B1 (ko) | 2011-02-22 |
| ATE322263T1 (de) | 2006-04-15 |
| EP1386605A1 (en) | 2004-02-04 |
| AU2003258539B2 (en) | 2008-08-21 |
| NO20050472L (no) | 2005-01-27 |
| DE60304477T2 (de) | 2006-12-14 |
| CA2491366A1 (en) | 2004-02-12 |
| JP4837916B2 (ja) | 2011-12-14 |
| SI1524975T1 (sl) | 2006-06-30 |
| EP1524975B1 (en) | 2006-04-05 |
| NO333297B1 (no) | 2013-04-29 |
| PT1524975E (pt) | 2006-07-31 |
| JP5564469B2 (ja) | 2014-07-30 |
| DK1524975T3 (da) | 2006-07-31 |
| ZA200500252B (en) | 2006-01-25 |
| IL165918A0 (en) | 2006-01-15 |
| BR0313091A (pt) | 2005-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5564469B2 (ja) | ロチゴチン投与のための改善された経皮送達系 | |
| US8617591B2 (en) | Transdermal delivery system for the administration of rotigotine | |
| US8246980B2 (en) | Transdermal delivery system | |
| CA2490573C (en) | Improved transdermal delivery system | |
| HK1083458B (en) | Improved transdermal delivery system | |
| HK1062650A (en) | Improved transdermal delivery system for the administration of rotigotine | |
| HK1062649A (en) | Improved transdermal delivery system | |
| HK1083459A (en) | Improved transdermal delivery system for the administration of rotigotine | |
| HK1227755A (en) | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110126 |